血管生成的新途径可能成为对抗耐药肿瘤的目标
Alternative pathways for blood vessel growth could become targets against drug-resistant tumors
西班牙卡洛斯三世心血管研究中心及其国际合作者发现,血管可以在缺乏VEGF-VEGFR2信号的情况下生成,这可能解释了肿瘤对血管生成抑制疗法产生耐药性的原因,并为开发新的抗癌疗法提供了新方向。
揭示了血管生成的新机制,可能为开发新的抗癌疗法提供新方向。
Researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), together with international collaborators, have uncovered previously unknown mechanisms that allow blood vessels to grow even in the absence of VEGF–VEGFR2 signaling, one of the best-known and most widely targeted pathways in clinical efforts to block tumor angiogenesis, growth and metastasis.
The findings may help explain why tumors develop resistance to anti-angiogenic therapies over time and identify alternative mechanisms of angiogenesis that could become new therapeutic targets to improve the efficacy of anti-angiogenic cancer treatments and reduce resistance to them.
Published in Nature, the study demonstrates that endothelial cells, which line the inside of blood vessels, can survive, proliferate and contribute to the formation of new vessels even in the absence of VEGF-VEGFR2 signaling, which had been considered essential for all aspects of angiogenesis. The results reveal that, rather than relying exclusively on this signaling pathway, some of these cells adapt, resist and are able to activate alternative molecular programs that enable angiogenesis.
Tracking vessel growth without VEGFR2
To investigate how blood vessels respond to the loss of VEGFR2, the research team directed by Rui Benedito, leader of the Molecular Genetics of Angiogenesis Group at CNIC and of the Department of Functional Genetics at the Max Planck Institute for Molecular Biomedicine (Germany), developed a mosaic genetics strategy that enabled them to distinguish and track normal endothelial cells alongside cells completely lacking VEGFR2 signaling throughout embryonic development and after birth.
"This enabled us to observe and compare how the two types of cell populations behaved throughout embryonic development and after birth," explains Dr. Irene García González, a researcher at CNIC and co-first author of the study.
The team found that the loss of VEGFR2 primarily affected endothelial cells that are actively involved in the formation of new blood vessels during an early stage of growth, but not in subsequent stages. The cells' responses also varied significantly depending on the organ. While blood vessels in the brain showed strong resistance to the loss of VEGFR2, endothelial cells in the heart, kidneys and liver proved more sensitive to its loss, displaying reduced survival and proliferation.
A shift toward venous identity
One of the study's most striking findings was that endothelial cells lacking VEGFR2 progressively recovered and increased their contribution to the vascular network, particularly in veins and the small vessels surrounding them.
This adaptation was accompanied by the acquisition of genetic characteristics typical of venous endothelial cells, a process the researchers describe as venousization. The study demonstrates that this change in cellular identity is crucial for enabling endothelial cells to survive and expand despite the absence of VEGFR2 signaling.
The team also identified the role of two additional VEGF receptors of the same family: VEGFR1 and VEGFR3. These receptors help sustain some endothelial cell survival and migration in the absence of VEGFR2 and act in parallel with the venousization genetic program.
These compensatory pathways reveal an unexpected degree of plasticity in endothelial cells and show that blood vessels have a much greater capacity to adapt to the loss of VEGF-VEGFR2 signaling than previously thought.
Compensatory pathways complicate cancer treatment
According to Benedito, co-leader of the study, "the findings may also help explain why tumors become resistant to treatments that block VEGF–VEGFR2 signaling."
The discovery challenges the long-held view that VEGF–VEGFR2 signaling is invariably essential for angiogenesis and suggests that therapies targeting VEGF-VEGFR2 signaling alone may not be sufficient to achieve durable responses. By identifying the molecular mechanisms that allow blood vessels to resist and bypass VEGFR2 signaling, the study opens new opportunities to develop combination therapies capable of blocking these compensatory pathways, with the potential to inhibit tumor angiogenesis and growth more effectively.
Publication details
Rui Benedito, Venousization enables angiogenesis in the absence of VEGFR signalling, Nature (2026). DOI: 10.1038/s41586-026-11224-w. www.nature.com/articles/s41586-026-11224-w
Journal information: Nature
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Alternative pathways for blood vessel growth could become targets against drug-resistant tumors (2026, November 4) retrieved 4 November 2026 from https://medicalxpress.com/news/2026-11-alternative-pathways-blood-vessel-growth.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com